CHMP positive for Agilus, intended for the treatment of malignant hyperthermia .- Norgine BV.
On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Agilus, intended for the treatment of malignant hyperthermia in combination with adequate support measures.The applicant for this medicinal product is Norgine B.V.
Agilus will be available as 120 mg powder for solution for injection. The active substance of Agilus is dantrolene sodium, hemiheptahydrate, a directly acting muscle relaxant (ATC code: M03CA01). Dantrolene is a skeletal muscle relaxant that binds to the ryanodine receptor -1 (RYR1), preventing the release of calcium from the sarcoplasmic reticulum.
The benefit of Agilus is reducing the mortality and morbidity of malignant hyperthermia as shown in the bridging study to the reference product, results from preclinical studies, clinical experience in case series, and consensus guidelines. Compared to the formulation of the reference medicine, mannitol and sodium hydroxide have been replaced with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and Macrogol 3350, which shortened the time for preparation and decreased the volume of water needed to dissolve each vial. Fast and ease of use are important clinical advantages for the treatment of an acute and life-threatening condition. The most common side effect of Agilus is muscle weakness.
Agilus is a hybrid medicine of Dantrolen IV 20 mg which has been authorised in the European Union since 1984. Agilus contains the same active substances as Dantrolen IV 20 mg but will be available in a higher 120 mg strength. In the formulation of Agilus, the mannitol and sodium hydroxide have been replaced with HP-beta-CD and Macrogol 3350 to shorten the preparation time and improve the ease of use. Studies have demonstrated the satisfactory quality of Agilus, and its bioequivalence to the reference product Dantrolen IV 20 mg.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins